Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

429179

	registered interest
	date	18/11/2015
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Castes: Discrimination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the compatibility of their decision to delay the publication of their feasibility study regarding establishing baseline data to evaluate the effectiveness of caste legislation with their commitment to open government.
	tabling member printed	Lord Avebury
	uin	HL3663
	answer	answer is ministerial correction date of answer 30/11/2015 answer text <p>This Government has been giving consideration to the legal position on caste discrimination in light of the <em>Tirkey v Chandhok</em> Employment Appeal Tribunal judgment which suggests there is an existing legal remedy for claims of caste-associated discrimination under the ‘ethnic origins’ element of Section 9 of the Equality Act 2010.</p><p>Our consideration of the research report commissioned by the coalition Government, designed to determine the feasibility of conducting a national survey to quantify the extent of caste discrimination in Britain, is part of this process.</p><p>We remain mindful of the Open Government Action Plan published by the Coalition Government in 2013, to the extent that this concerns the results of commissioned research.</p><br /> answering member printed Baroness Williams of Trafford grouped question UIN HL3664 HL3665 question first answered 30/11/2015 17:18:34 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	1665 label Biography information for Lord Avebury

429180

	registered interest
	date	18/11/2015
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Castes: Discrimination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of whether it is now possible to establish baseline data that could be used to determine whether the law on caste discrimination is working effectively.
	tabling member printed	Lord Avebury
	uin	HL3664
	answer	answer is ministerial correction date of answer 30/11/2015 answer text <p>This Government has been giving consideration to the legal position on caste discrimination in light of the <em>Tirkey v Chandhok</em> Employment Appeal Tribunal judgment which suggests there is an existing legal remedy for claims of caste-associated discrimination under the ‘ethnic origins’ element of Section 9 of the Equality Act 2010.</p><p>Our consideration of the research report commissioned by the coalition Government, designed to determine the feasibility of conducting a national survey to quantify the extent of caste discrimination in Britain, is part of this process.</p><p>We remain mindful of the Open Government Action Plan published by the Coalition Government in 2013, to the extent that this concerns the results of commissioned research.</p><br /> answering member printed Baroness Williams of Trafford grouped question UIN HL3663 HL3665 question first answered 30/11/2015 17:18:34 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	1665 label Biography information for Lord Avebury

429181

	registered interest
	date	18/11/2015
	answering body	Department for Education
	answering dept id	60
	answering dept short name	Education
	answering dept sort name	Education
	hansard heading	Castes: Discrimination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what further consideration they have given to whether amending the Equality Act 2010 to include the word "caste" would change or clarify the legal position, given the provisions already in place in section 9(5)(a) of that Act.
	tabling member printed	Lord Avebury
	uin	HL3665
	answer	answer is ministerial correction date of answer 30/11/2015 answer text <p>This Government has been giving consideration to the legal position on caste discrimination in light of the <em>Tirkey v Chandhok</em> Employment Appeal Tribunal judgment which suggests there is an existing legal remedy for claims of caste-associated discrimination under the ‘ethnic origins’ element of Section 9 of the Equality Act 2010.</p><p>Our consideration of the research report commissioned by the coalition Government, designed to determine the feasibility of conducting a national survey to quantify the extent of caste discrimination in Britain, is part of this process.</p><p>We remain mindful of the Open Government Action Plan published by the Coalition Government in 2013, to the extent that this concerns the results of commissioned research.</p><br /> answering member printed Baroness Williams of Trafford grouped question UIN HL3663 HL3664 question first answered 30/11/2015 17:18:34 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	1665 label Biography information for Lord Avebury

420484

	registered interest
	date	12/10/2015
	answering body	The Lord Chairman of Committees
	answering dept id	200
	answering dept short name
	answering dept sort name	Chairman of Committees (HoL)
	hansard heading	House of Lords: Catering
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask the Chairman of Committees what plans he has to end the subsidy for catering services in the House of Lords.
	tabling member printed	Lord Avebury
	uin	HL2459
	answer	answer is ministerial correction date of answer 21/10/2015 answer text <p>Catering and Retail Services seek to provide an appropriate level of service to support an active and busy parliamentary chamber, and to provide excellent value to the taxpayer. The catering subsidy has been reduced by 32% since 2007 and we are working hard to reduce it further through an ambitious Change Programme.</p><p>The unpredictable nature of parliamentary business – in terms of sitting days, recesses, the length of each sitting, and the level of attendance at the House for each sitting – means that staffing costs and wastage are higher than would be the case in purely commercial catering outlets. This makes an operating loss extremely difficult to avoid.</p><p>Furthermore, catering facilities are used by a wide range of people, not just Members. Venues such as the River Restaurant and Millbank House cafeteria are mainly intended to provide facilities for staff and other users such as the Metropolitan Police, contractors and others working on the Parliamentary Estate. It is good practice for large employers to provide cafeteria facilities for staff, particularly for organisations that operate outside normal office hours as is the case in the House of Lords. We pay all catering staff at least the London Living Wage and provide them with workplace pensions. We are proud to do so but it means our costs are higher than some commercial restaurants.</p><p>Given these factors, some element of tax-payer funding is appropriate, but the Administration is vigilant to ensure that public money is stewarded responsibly. Catering and Retail Services are also exploring novel ways to generate income in quieter times, such as opening the Peers’ Dining Room to the public in longer recesses. This helps to reduce the overall cost of the refreshment service to the tax payer, and so the subsidy.</p> answering member printed Lord Laming question first answered 21/10/2015 15:32:12 answering member 2079 label Biography information for Lord Laming
	tabling member	1665 label Biography information for Lord Avebury

425824

	registered interest
	date	03/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Stem Cells
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made in implementing the recommendations of the 2014 report of the UK Stem Cell Strategy Oversight Committee on the future of unrelated donor stem cell transplantation in the United Kingdom.
	tabling member printed	Lord Avebury
	uin	HL3222
	answer	answer is ministerial correction date of answer 12/11/2015 answer text <p>The Government continues to take forward work to deliver the recommendations in the 2014 report. We remain committed to improving stem cell transplantation services and doing all we can to help those in need of a transplant to find a suitable donor.</p><br /><p>Since 2011, the Department has provided its delivery partners, NHS Blood and Transplant and the Anthony Nolan, a total of £16 million in additional, new funding to improve stem cell transplantation services in the United Kingdom. A further £3 million investment was announced in March 2015.</p><br /><p>This funding has led to a tangible improvement in the availability of stem cells in the UK and the achievements include:</p><br /><p>- More UK patients received a stem cell transplant in 2014 than ever before;</p><br /><p>- Over 60% of black, Asian and minority ethnic (BAME) patients are now able to find a well matched donor compared to only 40% in 2010;</p><br /><p>- A single unified bone marrow donor registry has been created streamlining the provision of stem cells and reducing the time to provide cells from adult donors;</p><br /><p>- The proportion of patients receiving cord blood from UK donors has significantly increased; and</p><br /><p>- An increase in UK patients receiving a transplant from 802 in 2010/11 to 1,060 in 1013/14. The increased use of UK-sourced stem cells has meant that more donors than ever are available to donate leading to a significant cost saving by reducing the need to import stem cells.</p><br /> <br /> answering member printed Lord Prior of Brampton question first answered 12/11/2015 13:06:57 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1665 label Biography information for Lord Avebury

426401

	registered interest
	date	05/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which drugs have been delisted from the Cancer Drugs Fund; how many patients are currently being treated with each drug; and what steps they are taking to develop a new system for prescribing each drug.
	tabling member printed	Lord Avebury
	uin	HL3340
	answer	answer is ministerial correction date of answer 19/11/2015 answer text <p>Details of the drugs removed from the national Cancer Drugs Fund (CDF) list following re-prioritisation are shown in tables 1 and 2. The latest version of the list is available on NHS England’s website at: <a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a>. A copy is attached.</p><br /><table><tbody><tr><td colspan="2"><p>Table 1: Confirmation of previously notified drugs and indications delisted on 12 March 2015</p></td></tr><tr><td><p>Drug</p></td><td><p>Indication removed</p></td></tr><tr><td><p>Aflibercept</p></td><td><p>2nd line in combination with irinotecan-based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>Treatment of patients with indolent non-Hodgkin’s lymphoma who are refractory to rituximab</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with oxaliplatin–based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with irinotecan–based combination chemotherapy for metastatic colorectal cancer</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>1st line in combination with single agent fluoropyrimidine–based chemotherapy for metastatic colorectal cancer.</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>In combination with carboplatin and gemcitabine chemotherapy for recurrent platinum sensitive ovarian cancer</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Re-treatment in patients with relapsed myeloma</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Treatment of patients with relapsed Waldenstrom’s macroglobulinaemia</p></td></tr><tr><td><p>Bortezomib</p></td><td><p>Treatment of patients with relapsed mantle cell lymphoma</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of blast phase chronic myeloid leukaemia</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>2nd line in combination with irinotecan chemotherapy for metastatic colorectal cancer in patients with RAS wild type (non-mutated) tumours</p></td></tr><tr><td><p>Dasatinib</p></td><td><p>Treatment of the lymphoid blast phase of chronic myeloid leukaemia</p></td></tr><tr><td><p>Everolimus</p></td><td><p>Treatment of progressive unresectable or metastatic well differentiated neuroendocrine tumour of the pancreas</p></td></tr><tr><td><p>Lapatinib</p></td><td><p>In combination with capecitabine chemotherapy for HER-2 receptor positive locally advanced or metastatic breast cancer</p></td></tr><tr><td><p>Ofatumumab</p></td><td><p>Treatment of relapsed or refractory chronic lymphatic leukaemia</p></td></tr><tr><td><p>Pazopanib</p></td><td><p>Treatment of previously treated metastatic non-adipocytic soft tissue sarcomas</p></td></tr><tr><td><p>Pegylated liposomal doxorubicin</p></td><td><p>1st or 2nd line chemotherapy of angiosarcoma</p></td></tr><tr><td><p>Pegylated liposomal doxorubicin</p></td><td><p>Chemotherapy of primary malignant sarcomas of the heart and great vessels</p></td></tr><tr><td colspan="2"><p>Source: National Cancer Drugs Fund List Ver 6.0</p></td></tr></tbody></table><br /><table><tbody><tr><td colspan="2"><p>Table 2: Confirmation of previously notified drugs and indications delisted on 4 November 2015</p></td></tr><tr><td><p>Drug</p></td><td><p>Indication removed</p></td></tr><tr><td><p>Albumin bound Paclitaxel</p></td><td><p>First line treatment of advanced adenocarcinoma of the pancreas in combination with Gemcitabine</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>2<sup>nd </sup>or subsequent line treatment of chronic lymphatic leukaemia for patients whom fludarabine combination therapy is not a therapeutic option</p></td></tr><tr><td><p>Bendamustine</p></td><td><p>2<sup>nd </sup>and subsequent line of treatment of mantle cell lymphoma in patients who have not received previous Bendamustine</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>Treatment of patients with triple negative metastatic breast cancer and/or prior Taxane therapy</p></td></tr><tr><td><p>Bevacizumab</p></td><td><p>2<sup>nd </sup>or 3<sup>rd </sup>line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received Bevacizumab</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of chronic phase CML refractory to Nilotinib or Dasatinib</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of accelerated phase CML refractory to Nilotinib or Dasatinib</p></td></tr><tr><td><p>Bosutinib</p></td><td><p>Treatment of accelerated phase CML where there is significant intolerance to Dasatinib and Nilotinib.</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>3<sup>rd </sup>and subsequent line treatment of metastatic colorectal cancer as a single agent</p></td></tr><tr><td><p>Cetuximab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176</p></td></tr><tr><td><p>Dasatinib</p></td><td><p>Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy including Imatinib</p></td></tr><tr><td><p>Everolimus</p></td><td><p>2<sup>nd </sup>or 3<sup>rd </sup>line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy</p></td></tr><tr><td><p>Lenalidomide</p></td><td><p>2<sup>nd </sup>line treatment of multiple myeloma in patients who have contraindications to the use of Bortezomib</p></td></tr><tr><td><p>Panitumumab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent</p></td></tr><tr><td><p>Panitumumab</p></td><td><p>3rd and subsequent line treatment of metastatic colorectal cancer as a single agent in patients not treated to progression under NICE TA176</p></td></tr><tr><td><p>Pegylated Liposomal Doxorubicin</p></td><td><p>2nd line treatment of Fibromatosis</p></td></tr><tr><td><p>Peptide Receptor Radionucleotide Therapy (Lutetium177 Octreotate or Yttrium90 Octreotide/Octreotate)</p></td><td><p>Treatment of advanced neuro-endocrine tumours i.e. for pNETS after Sunitinib/chemotherapy, for mid-gut carcinoid, after octreotide/somatostatin therapies.</p></td></tr><tr><td><p>Pomalidomide</p></td><td><p>Treatment of relapsed and refractory multiple myeloma in patients who have received at least 2 prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy</p></td></tr><tr><td colspan="2"><p>Source: National Cancer Drugs Fund List Ver 6.0</p></td></tr></tbody></table><br /><p>NHS England publishes information on the number of patient applications for particular drugs/indications contained on the national CDF list on a quarterly basis. This information also includes the number of applications approved through the individual CDF request process. The latest information isattached as it is too long to be included in this answer. It is also available at:</p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a> and a copy of this is also attached.</p><br /><p>The Government is committed to the CDF and is working with NHS England and the National Institute for Health and Care Excellence on the future arrangements for the Fund.</p> answering member printed Lord Prior of Brampton attachment 1 file name ID3780736_HL3340 Library Depost CDF List.pdf title Cancer Drugs Fund List 2 file name CDF reporting template (1).xlsx title CDF Reporting template 3 file name HL3340 Library Depost patient numbers.docx title Patient Numbers question first answered 19/11/2015 14:54:51 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1665 label Biography information for Lord Avebury

426907

	registered interest
	date	09/11/2015
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Darfur: Crimes against Humanity
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, during the UK's Presidency of the UN Security Council this month, they will refer reports by Radio Dabanga of crimes against humanity in Darfur to the International Criminal Court for investigation.
	tabling member printed	Lord Avebury
	uin	HL3394
	answer	answer is ministerial correction date of answer 18/11/2015 answer text <p>The situation in Darfur has already been referred to the International Criminal Court (ICC) by the UN Security Council under UN Security Council Resolution 1593 (2005). As the prosecutor’s investigation is still ongoing, it could encompass any new allegations. However, such a decision would be for the Office of the Prosecutor of the Court to take. The UK remains a strong supporter of the ICC.</p> answering member printed Baroness Anelay of St Johns question first answered 18/11/2015 15:34:48 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1665 label Biography information for Lord Avebury

431538

	registered interest
	date	23/11/2015
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Bahrain: Detainees
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is their response to the recommendation by Human Rights Watch in its report on the treatment of detainees in Bahrain, <i>The Blood of People Who Don't Cooperate</i>, that the UK should suspend funding, support and training for security service reform until Bahrain enacts listed reforms and issues a standing invitation to the UN Special Rapporteur on Torture.
	tabling member printed	Lord Avebury
	uin	HL3801
	answer	answer is ministerial correction date of answer 01/12/2015 answer text <p>The British Government consistently and unreservedly condemns torture and cruel, inhuman or degrading treatment or punishment and it is a priority for us to combat it wherever and whenever it occurs. We are aware of ongoing allegations against Ministry of Interior personnel, and we have expressed our concerns to the authorities. The Government of Bahrain has previously committed to consider ratifying the Optional Protocol of the Convention Against Torture. The UK strongly supports this and we have been working with the authorities to share best practice on torture prevention measures. We also continue to ask the Government of Bahrain to allow a visit of the UN Special Rapporteur on Torture.</p><p>We welcome the progress made by Bahrain on their reform programme particularly in the areas of youth justice, the establishment and increasing effectiveness of the Ombudsman’s office, the Prisoner and Detainees’ Rights Commission and the reformed National Institute of Human Rights. We continue to work with the Government of Bahrain to ensure momentum and progress on its reforms, for the benefit of all Bahrainis.</p><p>The Government of Bahrain has asked the international community for their assistance in implementing the reforms necessary to improve the human rights situation, including in the security services. We strongly support them in their efforts and that is why we will continue to offer bilateral assistance for Bahrain’s reform programmes. In August, following a meeting with His Majesty King Hamad bin Isa Al Khalifa, the Prime Minister, my right hon. Friend the Member for Witney (Mr Cameron), reiterated the UK’s support for ongoing political reform in Bahrain but encouraged His Majesty to continue to demonstrate substantive progress in all areas. Our package of technical assistance is focused on strengthening human rights and the rule of law, in line with the Bahrain Independent Commission of Inquiry and the Universal Periodic Review.</p> answering member printed Baroness Anelay of St Johns question first answered 01/12/2015 16:40:57 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1665 label Biography information for Lord Avebury

433053

	registered interest
	date	30/11/2015
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Yemen: Military Intervention
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they have investigated claims by Human Rights Watch and Amnesty International that weapons supplied by the UK, such as Paveway IV missiles, have been used by Saudi Arabia to attack civilian targets in Yemen; and whether they have taken legal advice about the UK's responsibility for such attacks under international humanitarian law.
	tabling member printed	Lord Avebury
	uin	HL4013
	answer	answer is ministerial correction date of answer 08/12/2015 answer text The Ministry Of Defence monitors incidents of alleged international humanitarian law (IHL) violations using available information which in turn informs our overall assessment of IHL compliance in Yemen. We consider a range of evidence from government sources, foreign governments, the media and international non-governmental organisations. We are aware of reports, including from Human Rights Watch and Amnesty International, of alleged violations of IHL by the Saudi Arabian-led Coalition. We have received repeated assurances from the coalition that they are complying with IHL and we continue to engage with them on those assurances. The Saudi Arabian authorities have their own internal procedures for investigations and we encourage them to be open and transparent in this. The UK operates one of the most rigorous and transparent export control regimes in the world. All exports of arms and controlled military goods are assessed on a case-by-case basis against the Consolidated EU and National Arms Export Licensing, taking account of all relevant factors at the time of the application which include consideration of the risk of the goods being used to commit violations of human rights or international humanitarian law. answering member printed Baroness Anelay of St Johns question first answered 08/12/2015 15:20:42 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1665 label Biography information for Lord Avebury

433054

	registered interest
	date	30/11/2015
	answering body	Foreign and Commonwealth Office
	answering dept id	16
	answering dept short name	Foreign and Commonwealth Office
	answering dept sort name	Foreign and Commonwealth Office
	hansard heading	Yemen: Military Intervention
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the recommendations to the UN Security Council members in the Human Rights Watch report of 26 November, <i>What Military Target Was in My Brother's House: Unlawful Coalition Airstrikes in Yemen</i>.
	tabling member printed	Lord Avebury
	uin	HL4014
	answer	answer is ministerial correction date of answer 08/12/2015 answer text We are aware of the report released by Human Rights Watch on 26 November and its recommendations to the international community. The UN Security Council has made clear that sanctions will be applied to those individuals or entities who have been designated or listed for engaging in or providing support for acts that threaten the peace, security and stability of Yemen. We take all reports of alleged violations of International Humanitarian Law (IHL) in Yemen by any side to the conflict very seriously. We have raised our concerns with the Saudi Arabian government and have received assurances of IHL compliance and continue to engage with them on those assurances. We have also raised our concerns with the Houthis on the importance of compliance with IHL and international human rights law. We agree that all parties to the conflict have a responsibility to take all reasonable steps to allow and facilitate humanitarian access to facilitate immediate access to life-saving supplies both into and within Yemen. The Resolution on Yemen adopted at the September session of the Human Rights Council commits the Office of the High Commissioner of Human Rights to work with the Government of Yemen and produce an oral report on developments to be given at the next session in March 2016, and a written report to be published and presented to the Council in September 2016. We remain deeply concerned about the human rights situation in Yemen and will continue to work with all parties to find a political solution to the conflict. answering member printed Baroness Anelay of St Johns question first answered 08/12/2015 15:22:26 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	1665 label Biography information for Lord Avebury